P&G Healthcare Business Has $10 Bil. Potential – CEO Lafley
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble's healthcare unit could generate in excess of $10 bil. annually within a few years, according to CEO A.G. Lafley
You may also be interested in...
Novartis/P&G Enablex Deal Offers OTC Switch Option
Procter & Gamble is broadening its long-term Rx-to-OTC switch prospects with a co-promotion deal for Novartis' Enablex (darifenacin) extended-release tablets in the U.S
Novartis/P&G Enablex Deal Offers OTC Switch Option
Procter & Gamble is broadening its long-term Rx-to-OTC switch prospects with a co-promotion deal for Novartis' Enablex (darifenacin) extended-release tablets in the U.S
Novartis/P&G Enablex Deal Offers OTC Switch Option
Procter & Gamble is broadening its long-term Rx-to-OTC switch prospects with a co-promotion deal for Novartis' Enablex (darifenacin) extended-release tablets in the U.S